Skip to main content

Recent advances in the treatment of malignant astrocytoma.

Publication ,  Journal Article
Reardon, DA; Rich, JN; Friedman, HS; Bigner, DD
Published in: J Clin Oncol
March 10, 2006

Malignant gliomas, including the most common subtype, glioblastoma multiforme (GBM), are among the most devastating of neoplasms. Their aggressive infiltration in the CNS typically produces progressive and profound disability--ultimately leading to death in nearly all cases. Improvement in outcome has been elusive despite decades of intensive clinical and laboratory research. Surgery and radiotherapy, the traditional cornerstones of therapy, provide palliative benefit, while the value of chemotherapy has been marginal and controversial. Limited delivery and tumor heterogeneity are two fundamental factors that have critically hindered therapeutic progress. A novel chemoradiotherapy approach, consisting of temozolomide administered concurrently during radiotherapy followed by adjuvant systemic temozolomide, has recently demonstrated a meaningful, albeit modest, improvement in overall survival for newly diagnosed GBM patients. As cell-signaling alterations linked to the development and progression of gliomas are being increasingly elucidated, targeted therapies have rapidly entered preclinical and clinical evaluation. Responses to therapies that function via DNA damage have been associated with specific mediators of resistance that may also be subject to targeted therapies. Other approaches include novel locoregional delivery techniques to overcome barriers of delivery. The simultaneous development of multiple advanced therapies based on specific tumor biology may finally offer glioma patients improved survival.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

March 10, 2006

Volume

24

Issue

8

Start / End Page

1253 / 1265

Location

United States

Related Subject Headings

  • Temozolomide
  • Oncology & Carcinogenesis
  • Humans
  • Dacarbazine
  • DNA Methylation
  • Combined Modality Therapy
  • Central Nervous System Neoplasms
  • Astrocytoma
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006). Recent advances in the treatment of malignant astrocytoma. J Clin Oncol, 24(8), 1253–1265. https://doi.org/10.1200/JCO.2005.04.5302
Reardon, David A., Jeremy N. Rich, Henry S. Friedman, and Darell D. Bigner. “Recent advances in the treatment of malignant astrocytoma.J Clin Oncol 24, no. 8 (March 10, 2006): 1253–65. https://doi.org/10.1200/JCO.2005.04.5302.
Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006 Mar 10;24(8):1253–65.
Reardon, David A., et al. “Recent advances in the treatment of malignant astrocytoma.J Clin Oncol, vol. 24, no. 8, Mar. 2006, pp. 1253–65. Pubmed, doi:10.1200/JCO.2005.04.5302.
Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006 Mar 10;24(8):1253–1265.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

March 10, 2006

Volume

24

Issue

8

Start / End Page

1253 / 1265

Location

United States

Related Subject Headings

  • Temozolomide
  • Oncology & Carcinogenesis
  • Humans
  • Dacarbazine
  • DNA Methylation
  • Combined Modality Therapy
  • Central Nervous System Neoplasms
  • Astrocytoma
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis